Shire Plc Ads (SHPG) 203.05 $SHPG Shire to Show
Post# of 273318
Posted On: 09/26/2016 1:04:12 AM
Shire Plc Ads (SHPG) 203.05 $SHPG
Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting
PR Newswire - Fri Sep 23, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will showcase data across its global leading immunoglobulin (IG) portfolio during the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID), taking place September 21-24, 2016 in Barcelona.
SHPG: 203.05 (-1.17)
Shire Prices Public Offering of Senior Notes
PR Newswire Europe - Mon Sep 19, 6:29PM CDT
Shire plc announced today that its wholly owned subsidiary, Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC"
, priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes. The offering consists of four series of senior notes:
SHPG: 203.05 (-1.17)
District Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA®
PR Newswire Europe - Fri Sep 16, 3:51PM CDT
LEXINGTON, Massachusetts, September 16, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:00AM CDT
Shire plc (SHPG) announced that the FDA has granted approval for Cuvitru (Immune Globulin Subcutaneous (Human), 20% Solution) for the treatment of adult and pediatric patients with primary immunodeficiency.
ANIP: 66.64 (-0.17), SHPG: 203.05 (-1.17), LGND: 115.78 (-2.38), PCRX: 36.86 (-0.66)
Shire Announces U.S. FDA Approval of CUVITRUTM [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency
PR Newswire Europe - Wed Sep 14, 6:01AM CDT
LEXINGTON, Massachusetts, September 14, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
LifeSci Capital Initiates Coverage of Kamada
ACCESSWIRE - Mon Sep 12, 1:28PM CDT
Lead Product Glassia is Approved in Large and Growing AAT Deficiency Market; Report Available here: http://www.lifescicapital.com/equity-research/kamada/
SHPG: 203.05 (-1.17), KMDA: 4.96 (+0.01)
Research Reports Coverage on Healthcare Stocks -- Immune Pharma, Sanofi, Shire, and Universal Health Services
PR Newswire - Fri Sep 09, 7:05AM CDT
Stock-Callers.com redirects its attention to the Healthcare space, S&P healthcare sector has declined 3% in the past month due to political attacks. In the second quarter, however, the S&P Healthcare sector had the second highest earnings growth percentage of the major S&P sectors, up 7.5%, according to Thomson Reuters. Let us see where the following equities stand in the market today: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Universal Health Services Inc. (NYSE: UHS). These stocks research reports can be downloaded now by simply registering for free at:
UHS: 122.93 (-1.32), SHPG: 203.05 (-1.17), IMNP: 0.28 (unch), SNY: 38.35 (-0.22)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Thu Sep 08, 8:09AM CDT
LEXINGTON, Massachusetts, September 8, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17), MS: 31.91 (-0.33)
Shire plc: U.S. Securities and Exchange Commission Filings
PR Newswire Europe - Fri Sep 02, 5:31PM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
PR Newswire - Mon Aug 29, 11:40AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Xiidra(TM) (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the United States. An estimated 16 million adults in the U.S. are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment. The U.S. Food and Drug Administration (FDA) approved Xiidra on July 11, 2016.
SHPG: 203.05 (-1.17)
Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye
PR Newswire Europe - Thu Aug 25, 6:01AM CDT
LEXINGTON, Massachusetts, August 25, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting
PR Newswire - Fri Sep 23, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will showcase data across its global leading immunoglobulin (IG) portfolio during the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID), taking place September 21-24, 2016 in Barcelona.
SHPG: 203.05 (-1.17)
Shire Prices Public Offering of Senior Notes
PR Newswire Europe - Mon Sep 19, 6:29PM CDT
Shire plc announced today that its wholly owned subsidiary, Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC"
, priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes. The offering consists of four series of senior notes: SHPG: 203.05 (-1.17)
District Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA®
PR Newswire Europe - Fri Sep 16, 3:51PM CDT
LEXINGTON, Massachusetts, September 16, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:00AM CDT
Shire plc (SHPG) announced that the FDA has granted approval for Cuvitru (Immune Globulin Subcutaneous (Human), 20% Solution) for the treatment of adult and pediatric patients with primary immunodeficiency.
ANIP: 66.64 (-0.17), SHPG: 203.05 (-1.17), LGND: 115.78 (-2.38), PCRX: 36.86 (-0.66)
Shire Announces U.S. FDA Approval of CUVITRUTM [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency
PR Newswire Europe - Wed Sep 14, 6:01AM CDT
LEXINGTON, Massachusetts, September 14, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
LifeSci Capital Initiates Coverage of Kamada
ACCESSWIRE - Mon Sep 12, 1:28PM CDT
Lead Product Glassia is Approved in Large and Growing AAT Deficiency Market; Report Available here: http://www.lifescicapital.com/equity-research/kamada/
SHPG: 203.05 (-1.17), KMDA: 4.96 (+0.01)
Research Reports Coverage on Healthcare Stocks -- Immune Pharma, Sanofi, Shire, and Universal Health Services
PR Newswire - Fri Sep 09, 7:05AM CDT
Stock-Callers.com redirects its attention to the Healthcare space, S&P healthcare sector has declined 3% in the past month due to political attacks. In the second quarter, however, the S&P Healthcare sector had the second highest earnings growth percentage of the major S&P sectors, up 7.5%, according to Thomson Reuters. Let us see where the following equities stand in the market today: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Universal Health Services Inc. (NYSE: UHS). These stocks research reports can be downloaded now by simply registering for free at:
UHS: 122.93 (-1.32), SHPG: 203.05 (-1.17), IMNP: 0.28 (unch), SNY: 38.35 (-0.22)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Thu Sep 08, 8:09AM CDT
LEXINGTON, Massachusetts, September 8, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17), MS: 31.91 (-0.33)
Shire plc: U.S. Securities and Exchange Commission Filings
PR Newswire Europe - Fri Sep 02, 5:31PM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
PR Newswire - Mon Aug 29, 11:40AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Xiidra(TM) (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the United States. An estimated 16 million adults in the U.S. are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment. The U.S. Food and Drug Administration (FDA) approved Xiidra on July 11, 2016.
SHPG: 203.05 (-1.17)
Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye
PR Newswire Europe - Thu Aug 25, 6:01AM CDT
LEXINGTON, Massachusetts, August 25, 2016 /PRNewswire/ --
SHPG: 203.05 (-1.17)
(0)
(0)